Cas:143601-09-6 Curculigoside B manufacturer & supplier

We serve Chemical Name:Curculigoside B CAS:143601-09-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

Curculigoside B

Chemical Name:Curculigoside B
CAS.NO:143601-09-6
Synonyms:Curculigoside B
Molecular Formula:C21H24O11
Molecular Weight:452.40900
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:731.8ºC at 760mmHg
Density:1.528g/cm3
Index of Refraction:1.655
PSA:175.37000
Exact Mass:452.13200
LogP:

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like Curculigoside B chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Curculigoside B physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Curculigoside B Use and application,Curculigoside B technical grade,usp/ep/jp grade.


Related News: Coronaviruses (CoV) are a large family of viruses that cause illness ranging from the common cold to more severe diseases such as Middle East Respiratory Syndrome (MERS-CoV) and Severe Acute Respiratory Syndrome (SARS-CoV). A novel coronavirus (nCoV) is a new strain that has not been previously identified in humans. Curculigoside B manufacturer The outlook for a cure is clouded with theoretical uncertainties and high-profile failures. Pharmaceutical giants including Johnson & Johnson, Merck and Pfizer have ditched their projects on unsatisfactory data. Curculigoside B supplier Saudi Arabia��s state airline and Oman also suspended flights to China on Sunday in reaction to the coronavirus epidemic, according to Reuters. Curculigoside B vendor Saudi Arabia��s state airline and Oman also suspended flights to China on Sunday in reaction to the coronavirus epidemic, according to Reuters. Curculigoside B factory There’s still hope for this approach to treating Alzheimer’s disease despite the somewhat mixed results from this trial, said Rebecca Edelmayer, senior director of scientific engagement at the Alzheimer’s Association.